January 15, 2020

2020-01-17T10:00:29-05:00

https://images.c-span.org/Files/bae/20200117101105003_hd.jpg

The House Energy and Commerce Subcommittee on Health held a hearing to examine federal marijuana policy, including the implications of changing its drug schedule listing and the potential of cannabis research. Witnesses from the National Institute on Drug Abuse, the Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA) testified on current marijuana policy, the health effects of cannabis, and what steps Congress can take to allow for more research of cannabis compounds and products.

The House Energy and Commerce Subcommittee on Health held a hearing to examine federal marijuana policy, including the implications of… read more